AstraZeneca Korea announced on the 22nd that its SGLT-2 inhibitor Forxiga has additionally obtained indications for HFpEF and HFmrEF from the Ministry of Food and Drug Safety. The indication approved this time is to reduce the risk of death due to cardiovascular disease, hospitalization due to heart failure, and urgent hospital visits due to heart failure in NYHA class II-IV patients. This positions Forxiga as a treatment for patients with chronic heart failure across the entire ejection fraction range. This indication expansion is based on the DELIVER study. DELIVER is the largest clinical study of SGLT-2 inhibitors in heart failure patients with an LVEF of 40% or higher. 6263 patients with chronic heart failure with